Keith Pharmacology Research Group joins Emstopa as TRN increases stake

Emstopa Limited is a Sandwich-based biotechnology company founded in 2017. The firm develops a humanised antibody fragment designed to block tissue-type plasminogen activator (tPA). This technology aims to reverse tPA-induced bleeding and reduce haemorrhage in cardiac surgery, major trauma, and other clinical settings where thrombolytic agents are used.

The company's latest confirmation statement for the period ending 27 June 2026 shows Keith Pharmacology Research Group LLC has joined the cap table as a new shareholder with 310 ordinary shares. Simultaneously, TRN - The Research Network Ltd increased its holding by 59 percent. TRN - The Research Network Ltd now holds 312 ordinary shares, up from its previous position of 196 shares. These changes may signal a recent investment round into the Kent-based developer.

University of Tennessee Research Foundation remains on the cap table with a holding of 100 ordinary shares. No shareholders exited the company during this period. The entry of Keith Pharmacology Research Group LLC and the stake increase by TRN - The Research Network Ltd represent the primary shifts in ownership for the twelve months leading up to June 2026.